HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CORT118335

a glucocorticoid receptor antagonist; also a mineralocorticoid receptor ligand; structure in first source

Also Known As:

C118335

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - Uracil: 1493
        Thymine: 735
        CORT118335: 4

Experts

1.	Berman, Sarah: 1 article (01/2019)
2.	Caldwell, Jody L: 1 article (01/2019)
3.	Estrada, Christina M: 1 article (01/2019)
4.	Ghisays, Valentina: 1 article (01/2019)
5.	Nguyen, Elizabeth T: 1 article (01/2019)
6.	Solomon, Matia B: 1 article (01/2019)
7.	Streicher, Joshua: 1 article (01/2019)
8.	Ulrich-Lai, Yvonne: 1 article (01/2019)
9.	't Hoen, Peter A C: 1 article (12/2018)
10.	Belanoff, Joseph K: 1 article (12/2018)

Related Diseases

1.	Weight Gain 01/01/2019 - "CORT118335 (GR/MR modulator) prevents high-fat diet-induced weight gain and adiposity in mice, but the ability of this compound to reverse obesity-related symptoms is unknown. " 01/01/2016 - "Interestingly, only CORT118335 completely prevented the HFD-induced weight gain and white fat deposition, whereas mifepristone showed no effect on body weight and modestly increased subcutaneous fat mass. "
2.	Body Weight (Weight, Body) 01/01/2019 - "Notably, the body weight effects of CORT118335 persisted during a 2-wk treatment hiatus, suggesting prolonged effects of the compound. " 01/01/2016 - "Interestingly, only CORT118335 completely prevented the HFD-induced weight gain and white fat deposition, whereas mifepristone showed no effect on body weight and modestly increased subcutaneous fat mass. " 01/01/2019 - "Prolonged (18 days) treatment of CORT118335 (10 mg/kg) reversed body weight gain and adiposity in animals fed a high-fat diet for 13 wk. Surprisingly, this occurred despite a worsening of the lipid profile and glucose homeostasis as well as a disrupted diurnal corticosterone rhythm, suggesting GR agonistic effects in the periphery. "
3.	Non-alcoholic Fatty Liver Disease 12/01/2018 - "Our findings firmly demonstrate the potential use of CORT118335 in the treatment of NAFLD and underscore the potential of selective GR modulation in metabolic disease."
4.	Weight Loss (Weight Reduction) 01/01/2019 - "A 5-day treatment with CORT118335 at 30 mg/kg induced weight loss in rats fed a chow diet by decreasing food intake. "
5.	Prostatic Neoplasms (Prostate Cancer) 01/01/2017 - "Here, we report that two novel nonsteroidal and highly selective GR modulators (SGRM), CORT118335 and CORT108297, have the ability to block GR activity in prostate cancer and slow CRPC progression. "

Related Drugs and Biologics

1.	Mifepristone (RU 486)
2.	Lipids
3.	Glucose (Dextrose)
4.	Corticosterone
5.	CORT 108297